Gilead-Teva Deal Costs To Buyers Top $3.6B As Plaintiffs Rest
By Bonnie Eslinger · June 20, 2023, 9:59 PM EDT
Health care companies and health plans called their final witnesses Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login